MX2014010989A - Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiatricos. - Google Patents
Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiatricos.Info
- Publication number
- MX2014010989A MX2014010989A MX2014010989A MX2014010989A MX2014010989A MX 2014010989 A MX2014010989 A MX 2014010989A MX 2014010989 A MX2014010989 A MX 2014010989A MX 2014010989 A MX2014010989 A MX 2014010989A MX 2014010989 A MX2014010989 A MX 2014010989A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- psychiatric disorders
- iloperidone metabolite
- iloperidone
- metabolite
- Prior art date
Links
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical class COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 title 1
- 208000020016 psychiatric disease Diseases 0.000 title 1
- 239000003693 atypical antipsychotic agent Substances 0.000 abstract 1
- 229940127236 atypical antipsychotics Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
La presente invención se refiere un método de tratamiento de un paciente que sufre de un trastorno psiquiátrico que comprende administrar internamente al paciente una cantidad eficaz de R-P88, o una sal farmacéuticamente aceptable de la misma, o un éster de R-P88 o una sal farmacéuticamente aceptable de tal éster , una o dos veces por día, así como a una composición farmacéutica que comprende R-P88 o una sal farmacéuticamente aceptable de la misma, o un éster de R-P88 o una sal farmacéuticamente aceptable de un éster de R-P88, y un vehículo farmacéuticamente aceptable. Y al uso del R-P88 o una sal farmacéuticamente aceptable del mismo, o un éster de R-P88 o una sal farmacéuticamente aceptable de un éster de R-P88 para su uso en la fabricación de un medicamento útil para el tratamiento de un trastorno susceptible de tratamiento con un antipsicótico atípico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261610664P | 2012-03-14 | 2012-03-14 | |
PCT/US2013/031413 WO2013138602A1 (en) | 2012-03-14 | 2013-03-14 | An iloperidone metabolite for use in the treatment of psychiatric disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2014010989A true MX2014010989A (es) | 2015-03-10 |
Family
ID=48407766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014010989A MX2014010989A (es) | 2012-03-14 | 2013-03-14 | Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiatricos. |
Country Status (17)
Country | Link |
---|---|
US (3) | US10874659B2 (es) |
EP (2) | EP2825167B1 (es) |
JP (5) | JP2015510893A (es) |
KR (2) | KR20170008327A (es) |
CN (2) | CN104203240A (es) |
AU (2) | AU2013232014B2 (es) |
BR (1) | BR112014022687A8 (es) |
CA (1) | CA2865845C (es) |
CL (1) | CL2014002430A1 (es) |
CO (1) | CO7091183A2 (es) |
ES (2) | ES2677474T3 (es) |
IL (1) | IL234412B (es) |
IN (1) | IN2014DN08495A (es) |
MX (1) | MX2014010989A (es) |
RU (1) | RU2651710C2 (es) |
WO (1) | WO2013138602A1 (es) |
ZA (1) | ZA201406369B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170118830A (ko) | 2015-02-17 | 2017-10-25 | 반다 파마슈티칼즈, 인코퍼레이티드. | 조현병의 치료를 위한 일로페리돈 |
US11214827B2 (en) * | 2018-08-30 | 2022-01-04 | Vanda Pharmaceuticals Inc. | Genetic markers for enhancing efficacy of antipsychotic treatment with iloperidone |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5364866A (en) | 1989-05-19 | 1994-11-15 | Hoechst-Roussel Pharmaceuticals, Inc. | Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics |
US7029694B2 (en) | 2000-04-26 | 2006-04-18 | Watson Laboratories, Inc. | Compositions and methods for transdermal oxybutynin therapy |
ATE518845T1 (de) * | 2001-08-31 | 2011-08-15 | Novartis Pharma Gmbh | Optische isomere eines iloperidon-metaboliten |
BRPI0214821B8 (pt) | 2001-12-10 | 2021-07-27 | Novartis Ag | método para determinar a responsividade de indivíduo com distúrbio psicótico ao tratamento com loperidona |
TW200410955A (en) | 2002-07-29 | 2004-07-01 | Altana Pharma Ag | Novel salt of (S)-PANTOPRAZOLE |
GB0322994D0 (en) | 2003-10-01 | 2003-11-05 | Novartis Ag | Organic compounds |
ES2825949T3 (es) | 2004-09-30 | 2021-05-17 | Vanda Pharmaceuticals Inc | Métodos para administrar iloperidona |
US20100063093A1 (en) * | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
KR20090029200A (ko) * | 2006-05-22 | 2009-03-20 | 반다 파마슈티칼즈, 인코퍼레이티드. | 우울증 질환에 대한 치료 |
EP2134873B1 (en) | 2007-03-29 | 2015-05-06 | Vanda Pharmaceuticals Inc. | Method of predicting a predisposition to qt prolongation |
US9328387B2 (en) | 2007-09-10 | 2016-05-03 | Vanda Pharmaceuticals, Inc. | Antipsychotic treatment based on SNP genotype |
WO2009036100A2 (en) | 2007-09-10 | 2009-03-19 | Vanda Pharmaceuticals, Inc. | Prediction of qt prolongation based on snp genotype |
EP2416779B1 (en) | 2009-04-06 | 2016-03-09 | Vanda Pharmaceuticals Inc. | Method of predicting a predisposition to qt prolongation based on bai3 gene sequence or product thereof |
WO2010117937A1 (en) | 2009-04-06 | 2010-10-14 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to qt prolongation |
ES2673603T3 (es) | 2009-04-06 | 2018-06-25 | Vanda Pharmaceuticals Inc. | Método de tratamiento basado en polimorfismos del gen KCNQ1 |
WO2010117941A1 (en) | 2009-04-06 | 2010-10-14 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof |
ES2533091T3 (es) | 2009-05-15 | 2015-04-07 | Vanda Pharmaceuticals Inc. | Tratamiento antipsicótico basado en genotipo de SNP de DRD2 o ANKK1 |
-
2013
- 2013-03-14 ES ES13721817.8T patent/ES2677474T3/es active Active
- 2013-03-14 BR BR112014022687A patent/BR112014022687A8/pt not_active Application Discontinuation
- 2013-03-14 KR KR1020177001093A patent/KR20170008327A/ko active Search and Examination
- 2013-03-14 WO PCT/US2013/031413 patent/WO2013138602A1/en active Application Filing
- 2013-03-14 EP EP13721817.8A patent/EP2825167B1/en active Active
- 2013-03-14 JP JP2015500615A patent/JP2015510893A/ja active Pending
- 2013-03-14 US US14/384,401 patent/US10874659B2/en active Active
- 2013-03-14 EP EP18152636.9A patent/EP3345603B1/en active Active
- 2013-03-14 CN CN201380013841.XA patent/CN104203240A/zh active Pending
- 2013-03-14 IN IN8495DEN2014 patent/IN2014DN08495A/en unknown
- 2013-03-14 CN CN201810683727.2A patent/CN108938632A/zh active Pending
- 2013-03-14 RU RU2014141112A patent/RU2651710C2/ru active
- 2013-03-14 MX MX2014010989A patent/MX2014010989A/es active IP Right Grant
- 2013-03-14 CA CA2865845A patent/CA2865845C/en active Active
- 2013-03-14 ES ES18152636T patent/ES2773711T3/es active Active
- 2013-03-14 AU AU2013232014A patent/AU2013232014B2/en active Active
- 2013-03-14 KR KR1020147026434A patent/KR20140121487A/ko active Search and Examination
-
2014
- 2014-08-29 ZA ZA2014/06369A patent/ZA201406369B/en unknown
- 2014-09-01 IL IL234412A patent/IL234412B/en active IP Right Grant
- 2014-09-12 CL CL2014002430A patent/CL2014002430A1/es unknown
- 2014-10-09 CO CO14224666A patent/CO7091183A2/es unknown
-
2016
- 2016-05-30 AU AU2016203591A patent/AU2016203591B2/en active Active
- 2016-11-07 JP JP2016217680A patent/JP2017061506A/ja active Pending
-
2018
- 2018-09-10 JP JP2018169090A patent/JP7151029B2/ja active Active
-
2020
- 2020-09-28 JP JP2020162569A patent/JP2021001221A/ja active Pending
- 2020-09-30 US US17/039,769 patent/US20210015809A1/en not_active Abandoned
-
2022
- 2022-12-01 JP JP2022192922A patent/JP2023022243A/ja active Pending
-
2023
- 2023-09-26 US US18/373,205 patent/US20240016791A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL255547A (en) | Treatment of vasculitis with prosticyclin and mesenchymal stem cells | |
TWD165363S (zh) | 錶殼 | |
EP2954046A4 (en) | Oligodendrocyte precursor cells derived from isolated pluripotent cells to treat myelin disease | |
TWD158794S (zh) | 遮瑕膏容器 | |
TWD158887S (zh) | 粉餅盒 | |
TWD162033S (zh) | 手錶 | |
TWD159981S (zh) | 化粧品容器 | |
TWD166111S (zh) | 速克達摩托車 | |
TWD171869S (zh) | 速克達摩托車 | |
BR112015008381A2 (pt) | aquecedor portátil ativado por oxigênio com almofada de eletrólito | |
TWD162323S (zh) | 個人電腦 | |
MX2014010989A (es) | Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiatricos. | |
TWD163566S (zh) | 心電圖監視器 | |
NZ631749A (en) | Methods of treating cancer using angiogenin or an angiogenin agonist | |
TWD172356S (zh) | 錶殼 | |
TWD170042S (zh) | 塗抹器之部分 | |
UA70542U (ru) | Способ психофармакотерапии компьютерной зависимости | |
TWD166198S (zh) | 按摩器 | |
MX369774B (es) | Uso de pregn-4-en-20-in-3-ona para el tratamiento de trastornos depresivos. | |
TWD160632S (zh) | 包裝用容器 | |
TWD158466S (zh) | 電位治療器 | |
TWD167418S (zh) | 開罐器 | |
UA91089U (uk) | Застосування препарату "біоглобін-у" як препарату для корекції гіпотиреоїдних станів в експерименті | |
TWD161589S (zh) | 皮膚清潔裝置 | |
TWD159866S (zh) | 眼鏡(一) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |